Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00459914
Status:
COMPLETED
Last Update Posted:
2009-01-29
First Post:
2007-04-11
Brief Title:
Sleep Apnea and Refractory Hypertension Prevalence and Effect of CPAP Treatment
Sponsor:
Fundacio Catalana de Pneumologia
Organization:
Fundacio Catalana de Pneumologia
Study Overview
Official Title:
Sleep Apnea in Patients With Refractory Hypertension Study of the Prevalence and the Effect of CPAP Treatment on Blood Pressure Control Endothelial Dysfunction and Angiogenesis
Status:
COMPLETED
Status Verified Date:
2009-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A small number of uncontrolled studies have shown a high prevalence of sleep apnea in patients with refractory hypertension and that CPAP treatment achieves a significant reduction of blood pressure in the short term
The purpose of this study is to assess the prevalence of sleep apnea in patients with refractory hypertension and the effects of continuous positive pressure treatment on systemic blood pressure and on serum markers of endothelial dysfunction and angiogenesis
The purpose of this study is to assess the prevalence of sleep apnea in patients with refractory hypertension and the effects of continuous positive pressure treatment on systemic blood pressure and on serum markers of endothelial dysfunction and angiogenesis
Detailed Description:
We assess the prevalence of an apnea hypopnea index AHI 5 in patients with refractory hypertension referred from a hypertension clinic Patients with an AHI 15 are randomized to either continuing their usual pharmacological treatment alone or adding CPAP to their usual treatment during a 3 month period
The main endpoint is the comparison of the mean 24h systolic and diastolic blood pressure as assessed by ambulatory blood pressure monitoring between both treatment arms The secondary endpoint is to assess changes in serum markers of endothelial dysfunction and angiogenesis
The main endpoint is the comparison of the mean 24h systolic and diastolic blood pressure as assessed by ambulatory blood pressure monitoring between both treatment arms The secondary endpoint is to assess changes in serum markers of endothelial dysfunction and angiogenesis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None